文献速递糖尿病肥胖与代谢综合征

21世纪胰岛素抵抗:旧问题的新视角——2025糖尿病、糖尿病护理与糖尿病学专家论坛

Insulin resistance in the 21st century: new takes on an old problem-2025 Diabetes, Diabetes Care, and Diabetologia Expert Forum.
PubMed 文献 · Diabetologia · 2026-09-28

2025年9月,Diabetes、Diabetes Care和Diabetologia编辑在EASD第61届年会前召集专家论坛,综述胰岛素抵抗最新研究。专家提出胰岛素抵抗并非单一均匀病理状态,而是高度可塑的适应性/适应不良、急性/慢性反应集合,并呼吁开发真正胰岛素增敏剂。

要点

  • 胰岛素抵抗是2型糖尿病等多种代谢病的标志,但生物学复杂且概念方法受限。
  • 专家挑战传统单一均匀观点,将其视为全身多组织高度可塑的异质性反应。
  • 现有治疗多间接改善胰岛素抵抗,需研发真正胰岛素增敏剂及靶向通路缺陷。

核心结论

  • 胰岛素抵抗应被视为多样、高度可塑的适应性与适应不良反应集合,而非单一均匀病理状态。
  • 需继续研究导致胰岛素抵抗变异的复杂因素及通路特异性缺陷,以开发靶向有效疗法。

研究设计与样本

  • 2025年9月,Diabetes、Diabetes Care和Diabetologia编辑在EASD第61届年会前召集专家论坛,综述最新研究并推荐未来研究方向。

主要发现

  • 胰岛素抵抗在全身不同部位、生物过程、个体间及不同生理环境条件下表现不同。
  • 现有治疗选项对胰岛素抵抗多为间接效应,有前景策略可指导真正胰岛素增敏剂开发。

临床怎么用

  • 临床应认识胰岛素抵抗的异质性和可塑性,避免单一均匀处理。
  • 关注通路特异性缺陷,为未来靶向治疗和真正胰岛素增敏剂研发提供方向。

局限性

  • 原文未报告具体研究样本量、数值阈值或疗效数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Insulin resistance is a hallmark of type 2 diabetes and several other metabolic diseases. However, efforts to improve insulin resistance are hindered by the biological complexity inherent to insulin action, as well as conceptual and methodological limitations to date. In September 2025, the editors of Diabetes, Diabetes Care and Diabetologia convened an Expert Forum in advance of the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD). Participants reviewed the latest research, clarified key concepts and recommended future research priorities. Their insights were presented at a symposium during the EASD meeting and are offered in more detail here. The authors challenge the historical view of insulin resistance as a single, uniform pathophysiological condition, describing it instead as a diverse and highly plastic set of adaptive, maladaptive, acute and chronic responses that manifest differently throughout the body, in numerous biological processes, within and among individuals, and under various physiological and environmental conditions. They describe existing methods of measuring whole-body and tissue-specific insulin resistance and offer a primer on the two main insulin signalling networks. Next, they review current therapeutic options, which offer mostly indirect effects on insulin resistance, and highlight promising strategies to inform the eventual development of true insulin-sensitising agents. The authors call for continued investigation of the complex factors accounting for variability in insulin resistance, as well as pathway-specific defects, with the ultimate goal of developing targeted and more effective therapies for type 2 diabetes and the broader spectrum of cardiometabolic complications and related comorbidities.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Gastaldelli A, Choi E, Conde-Knape K, et al. Insulin resistance in the 21st century: new takes on an old problem-2025 Diabetes, Diabetes Care, and Diabetologia Expert Forum. Diabetologia. 2026. PMID: 42803809. doi:10.1007/s00125-026-06853-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。